Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRMD
stocks logo

CRMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
127.34M
+308.02%
0.816
+270.78%
127.41M
+226.02%
0.720
+140%
127.57M
+221.04%
0.720
+157.14%
Estimates Revision
The market is revising Upward the revenue expectations for CorMedix Inc. (CRMD) for FY2025, with the revenue forecasts being adjusted by 29.16% over the past three months. During the same period, the stock price has changed by -14.19%.
Revenue Estimates for FY2025
Revise Upward
up Image
+29.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+62.38%
In Past 3 Month
Stock Price
Go Down
down Image
-14.19%
In Past 3 Month
Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 18.40 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 18.40 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.640
sliders
Low
14.00
Averages
18.40
High
22.00
Current: 10.640
sliders
Low
14.00
Averages
18.40
High
22.00
H.C. Wainwright
Brandon Folkes
Buy
maintain
$17 -> $18
2025-11-13
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$17 -> $18
2025-11-13
maintain
Buy
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on CorMedix to $18 from $17 and keeps a Buy rating on the shares post the Q3 report. With the acquisition of Melinta now closed, CorMedix has a more diversified business going into 2026, the analyst tells investors in a research note.
RBC Capital
Gregory Renza
Outperform
maintain
$21 -> $22
2025-10-21
Reason
RBC Capital
Gregory Renza
Price Target
$21 -> $22
2025-10-21
maintain
Outperform
Reason
RBC Capital analyst Gregory Renza raised the firm's price target on CorMedix to $22 from $21 and keeps an Outperform rating on the shares. CorMedix raised their pro-forma 2025 revenue guidance to $375M+ and reported an $85M+ quarter for DefenCath, showing strong quarter over quarter growth for DefenCath, the analyst tells investors in a research note. DefenCath still has room to grow within existing dialysis organizations and the post-TDAPA cliff is manageable, the firm argues.
Boral Capital
D. Boral
Hold
to
Buy
upgrade
$14
2025-10-20
Reason
Boral Capital
D. Boral
Price Target
$14
2025-10-20
upgrade
Hold
to
Buy
Reason
D. Boral Capital upgraded CorMedix to Buy from Hold with a $14 price target after the company reported preliminary Q3 results. The "robust" sales in Q3 and visibility into near-term operating synergies, as well as the recent stock pullback, lead the firm to raise its rating and reinstate its $14 target.
H.C. Wainwright
Brandon Folkes
Buy
downgrade
$20 -> $17
2025-08-08
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20 -> $17
2025-08-08
downgrade
Buy
Reason
H.C. Wainwright analyst Brandon Folkes lowered the firm's price target on CorMedix to $17 from $20 and keeps a Buy rating on the shares. The firm views the acquisition of Melinta Therapeutics as neutral.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$20
2025-06-30
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20
2025-06-30
initiated
Buy
Reason
Boral Capital
D. Boral
Buy
to
Hold
downgrade
2025-06-30
Reason
Boral Capital
D. Boral
Price Target
2025-06-30
downgrade
Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for CorMedix Inc (CRMD.O) is 3.80, compared to its 5-year average forward P/E of -4.97. For a more detailed relative valuation and DCF analysis to assess CorMedix Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.97
Current PE
3.80
Overvalued PE
35.59
Undervalued PE
-45.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.35
Undervalued EV/EBITDA
-6.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4105.17
Current PS
0.00
Overvalued PS
18281.53
Undervalued PS
-10071.19
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CRMD News & Events

Events Timeline

(ET)
2025-11-12
07:39:20
CorMedix Projects FY25 Pro Forma Revenue Between $390M and $410M
select
2025-11-12
07:38:22
CorMedix Announces Q3 Earnings Per Share of $1.26, Exceeding Consensus Estimate of 63 Cents
select
2025-10-23 (ET)
2025-10-23
08:35:14
CorMedix awarded Innovative Technology status by Vizient
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-04NASDAQ.COM
Daily Upgrade Report for Validea's Joel Greenblatt Strategy - December 4, 2025

  • Aveanna Healthcare Holdings Inc. Rating: The stock rating for Aveanna Healthcare Holdings Inc. (AVAH) improved from 80% to 90% based on its strong fundamentals and valuation, indicating strong interest from the Earnings Yield Investor model by Joel Greenblatt.

  • CorMedix Inc. Rating: CorMedix Inc. (CRMD) also saw its rating rise dramatically from 0% to 90%, reflecting significant improvement in its underlying fundamentals and stock valuation, suggesting strong interest according to the same investment strategy.

  • Company Descriptions: Aveanna Healthcare provides diversified home care services, including private duty nursing and hospice care, while CorMedix focuses on developing therapeutic products to prevent and treat serious health conditions, particularly related to catheter-related infections.

  • About Joel Greenblatt and Validea: Joel Greenblatt is known for his "Magic Formula" investment strategy, which has historically outperformed the market, and Validea is an investment research service that applies strategies from various successful investors, including Greenblatt.

[object Object]
Preview
7.5
12-03NASDAQ.COM
REGN and Tessera Partner to Create Gene-Editing Treatment for AATD

  • Collaboration with Tessera Therapeutics: Regeneron Pharmaceuticals has entered a collaboration with Tessera Therapeutics to develop TSRA-196, a gene editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), sharing development costs and profits equally.

  • Regulatory Approvals and Product Performance: Regeneron has received FDA approval for Eylea HD and a label expansion for Libtayo, while facing challenges with declining Eylea sales due to competition, prompting the development of a higher dose version.

  • Financial Outlook and Stock Performance: Regeneron’s stock has increased by 5.3% year-to-date, but the decline in Eylea sales poses a significant challenge, despite positive developments in its oncology portfolio and partnerships.

  • Market Comparisons and Rankings: Regeneron holds a Zacks Rank #3 (Hold), while competitors like CorMedix and ANI Pharmaceuticals have better rankings and have shown significant stock performance improvements in recent months.

[object Object]
Preview
8.5
12-03NASDAQ.COM
BHC Shares Rise Following Solta's Acquisition of Shibo's Aesthetics Distribution Division

  • Bausch Health Acquisition: Bausch Health, Inc. shares rose 11% following the acquisition of Wuhan Shibo Zhenmei Technology, enhancing Solta Medical's distribution capabilities in China's growing aesthetics market.

  • Financial Performance: Bausch Health reported better-than-expected third-quarter results, with Solta Medical's revenues increasing by 25% year-over-year, although the company still faces significant long-term debt of $21 billion.

  • Market Positioning: The acquisition positions Solta Medical to meet rising demand for aesthetic treatments in China, improving operational efficiency and revenue potential in the region.

  • Stock Rankings: Bausch Health holds a Zacks Rank #3 (Hold), while other biotech stocks like CorMedix, Amicus Therapeutics, and ANI Pharmaceuticals are ranked #1 (Strong Buy), indicating stronger market performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CorMedix Inc (CRMD) stock price today?

The current price of CRMD is 10.64 USD — it has increased 3.1 % in the last trading day.

arrow icon

What is CorMedix Inc (CRMD)'s business?

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

arrow icon

What is the price predicton of CRMD Stock?

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 18.40 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CorMedix Inc (CRMD)'s revenue for the last quarter?

CorMedix Inc revenue for the last quarter amounts to 104.28M USD, increased 810.22 % YoY.

arrow icon

What is CorMedix Inc (CRMD)'s earnings per share (EPS) for the last quarter?

CorMedix Inc. EPS for the last quarter amounts to 1.26 USD, decreased -2620.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for CorMedix Inc (CRMD)'s fundamentals?

The market is revising Upward the revenue expectations for CorMedix Inc. (CRMD) for FY2025, with the revenue forecasts being adjusted by 29.16% over the past three months. During the same period, the stock price has changed by -14.19%.
arrow icon

How many employees does CorMedix Inc (CRMD). have?

CorMedix Inc (CRMD) has 64 emplpoyees as of December 05 2025.

arrow icon

What is CorMedix Inc (CRMD) market cap?

Today CRMD has the market capitalization of 838.32M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free